Killing Two Birds with One Stone: Is the COVID-19 Vaccination Campaign an Opportunity to Improve Adherence to Cancer Screening Programmes? The Challenge of a Pilot Project in a Large Local Health Authority in Rome.
COVID-19 vaccination campaign
healthy behavior
prevention
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
23 Feb 2023
23 Feb 2023
Historique:
received:
22
01
2023
revised:
17
02
2023
accepted:
20
02
2023
medline:
31
3
2023
entrez:
30
3
2023
pubmed:
31
3
2023
Statut:
epublish
Résumé
The COVID-19 pandemic has affected health services worldwide. The suspension of cancer screening programs during the lockdown period, coupled with the other measures taken to limit the SARS-CoV-2 spread, contributed to the idea that cancer preventive interventions are deferrable. In this opinion paper, we present some data on cancer screening coverage in one of the largest Local Health Authorities in Italy in recent years. Within this context, we introduce the benefits of a pilot project in which we took advantage of the great attention on the COVID-19 vaccination campaign to improve screening uptake. In this project, we offered men and women eligible for cancer screening the opportunity to book appointments while waiting to be vaccinated. In addition, trained healthcare personnel were available on-site to discuss any barriers to participation with the attendees. Despite the project having only just started, preliminary results are encouraging, with positive feedback from the attendees. In conclusion, we advocate for the need to adopt a comprehensive approach when it comes to population health, and we use this project as an example to discuss how it is possible to contribute to minimizing the long-term impact of the COVID-19 pandemic with resources already in place.
Identifiants
pubmed: 36992105
pii: vaccines11030523
doi: 10.3390/vaccines11030523
pmc: PMC10057646
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JMIR Cancer. 2020 Oct 29;6(2):e21697
pubmed: 33027039
Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):5-8
pubmed: 26405771
J Med Screen. 2016 Dec;23(4):179-185
pubmed: 26946420
J Clin Oncol. 2016 Jan 1;34(1):14-9
pubmed: 26578618
Eur J Cancer. 2009 Jan;45(1):127-38
pubmed: 19038540
PLoS One. 2021 Jul 12;16(7):e0254523
pubmed: 34252157
Ann Ist Super Sanita. 2022 Jan-Mar;58(1):16-24
pubmed: 35324470
BMJ Open. 2018 Sep 19;8(9):e021653
pubmed: 30232106
Int J Environ Res Public Health. 2020 Dec 31;18(1):
pubmed: 33396424
Health Policy. 2018 Apr;122(4):422-430
pubmed: 29454541
Eur Heart J. 2020 Jun 7;41(22):2083-2088
pubmed: 32412631
BMC Public Health. 2013 May 13;13:464
pubmed: 23663511
Acta Biomed. 2020 Apr 10;91(3-S):175-179
pubmed: 32275287
Vaccines (Basel). 2022 Oct 29;10(11):
pubmed: 36366341
Int J Environ Res Public Health. 2020 Dec 18;17(24):
pubmed: 33352883
Future Oncol. 2021 Oct;17(28):3757-3775
pubmed: 34378403
Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):9-18
pubmed: 26405772
Vaccine. 2022 Apr 20;40(18):2540-2545
pubmed: 35341646
Value Health. 2017 Sep;20(8):1048-1057
pubmed: 28964436
Semin Oncol Nurs. 2017 May;33(2):121-128
pubmed: 28343835
Cancers (Basel). 2021 Mar 30;13(7):
pubmed: 33808101
J Gastrointestin Liver Dis. 2022 Sep 16;31(3):356-358
pubmed: 36112709
Eur J Cancer Care (Engl). 2018 Sep;27(5):e12905
pubmed: 30178893
BMJ Open. 2021 Mar 16;11(3):e045343
pubmed: 33727273
Prev Med. 2022 Feb;155:106927
pubmed: 34954244